Mitchell Mcleod Pugh & Williams Inc. Has $948,000 Stake in Stryker Corporation $SYK

Mitchell Mcleod Pugh & Williams Inc. lifted its position in Stryker Corporation (NYSE:SYK) by 309.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,647 shares of the medical technology company’s stock after purchasing an additional 2,000 shares during the quarter. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Stryker were worth $948,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Godfrey Financial Associates Inc. bought a new stake in Stryker in the fourth quarter valued at $26,000. United Financial Planning Group LLC bought a new stake in Stryker in the third quarter valued at $27,000. CGC Financial Services LLC bought a new stake in Stryker in the fourth quarter valued at $29,000. Strive Asset Management LLC bought a new stake in Stryker in the third quarter valued at $30,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Stryker in the third quarter valued at $34,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on SYK. Canaccord Genuity Group lowered their price target on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. UBS Group lowered their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, BTIG Research decreased their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $395.33.

Stryker Stock Down 1.8%

NYSE:SYK opened at $308.50 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market cap of $118.27 billion, a PE ratio of 35.71, a PEG ratio of 1.98 and a beta of 0.78. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The stock has a 50-day simple moving average of $317.20 and a 200 day simple moving average of $344.64.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the business earned $2.84 earnings per share. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last three months. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.